2023
End-of-Life Systemic Oncologic Treatment in the Immunotherapy Era: The Role of Race, Insurance, and Practice Setting
Canavan M, Wang X, Ascha M, Miksad R, Showalter T, Calip G, Gross C, Adelson K. End-of-Life Systemic Oncologic Treatment in the Immunotherapy Era: The Role of Race, Insurance, and Practice Setting. Journal Of Clinical Oncology 2023, 41: 4729-4738. PMID: 37339389, PMCID: PMC10602547, DOI: 10.1200/jco.22.02180.Peer-Reviewed Original ResearchConceptsSystemic treatmentEnd of lifeWhite patientsBlack patientsOdds ratioLarge real-world populationPractice settingsTreatment ratesPatient-level factorsEmergency department useIntensive care unitReal-world populationDay of deathImmunotherapy eraSystemic therapyOncologic treatmentCare unitDeidentified databaseDepartment usePatient raceInsurance typeMetastatic cancerDownstream careMedicaid patientsHigher odds
2021
Differences by race in systemic oncologic end-of-life (EOL) care among patients with cancer.
Adelson K, Wang X, Ascha M, Miksad R, Showalter T, Calip G, Gross C, Canavan M. Differences by race in systemic oncologic end-of-life (EOL) care among patients with cancer. Journal Of Clinical Oncology 2021, 39: 137-137. DOI: 10.1200/jco.2020.39.28_suppl.137.Peer-Reviewed Original ResearchBlack patientsWhite patientsAggressive EOL careRetrospective cohort studyPractice-level factorsPractice-level characteristicsRacial differencesDe-identified databaseLogistic regression modelsAnti-cancer therapyElectronic health recordsImmunotherapy eraCohort studyICI useOncologic treatmentPayer cohortHigh patientEOL careAdjusted ratesOutcome measuresEOL treatmentMedicaid coveragePatientsPhysician ratioRoutine practicePatient- and provider-level predictors of mortality among patients with metastatic renal cell carcinoma receiving oral anticancer agents.
Spees L, Dinan M, Jackson B, Baggett C, Wilson L, Greiner M, Kaye D, Zhang T, George D, Scales C, Pritchard J, Leapman M, Gross C, Wheeler S. Patient- and provider-level predictors of mortality among patients with metastatic renal cell carcinoma receiving oral anticancer agents. Journal Of Clinical Oncology 2021, 39: 116-116. DOI: 10.1200/jco.2020.39.28_suppl.116.Peer-Reviewed Original ResearchMetastatic renal cell carcinomaOral anti-cancer agentsPatients' clinical characteristicsProvider-level factorsCause mortalityRenal cell carcinomaClinical characteristicsHazard ratioMetastatic diagnosisCell carcinomaState cancer registry dataCox proportional hazards modelProvider-level predictorsLower overall survivalOral anticancer agentsCancer registry dataReal-world populationProportional hazards modelSkilled nursing facilitiesProvider Enumeration SystemAnti-cancer agentsIndex dateOverall survivalPatient demographicsBlack patientsMediators of racial disparity in the use of prostate MRI.
Leapman M, Dinan M, Pasha S, Washington S, Ma X, Gross C. Mediators of racial disparity in the use of prostate MRI. Journal Of Clinical Oncology 2021, 39: 6554-6554. DOI: 10.1200/jco.2021.39.15_suppl.6554.Peer-Reviewed Original ResearchProstate cancerRacial disparitiesProstate MRIMRI useArea-level measuresObserved racial disparitiesEligible patientsPathologic factorsDual eligibilityWhite patientsBlack patientsSEER regionMedicare databaseCancer careSix-month periodPatientsSociodemographic factorsCancerMRIZip codesOlder AmericansMediatorsDiagnostic toolObserved disparitiesHigh-poverty areas